Back

Six-month renal marker trajectories with azilsartan–indapamide versus azilsartan–nitrendipine in essential hypertension: a pragmatic comparative study

31 August 2026 (09:15 - 10:00)
Organised by: Logo
Congress Presentation Part of: Hypertension treatment (2) Clinical ESC2026 Premium Access ESC Congress 2026 European Society of Cardiology

About the speaker

Photo
Assistant Professor Zaringiz Mashkurova

Republican Specialized Scientific Practical Medical Center Of Cardiology, Tashkent (Uzbekistan)

5 More presentations in this session

Presentation thumbnail
The effect of eplerenone vs irbesartan as first line therapy in obese hypertensive patients on left ventricular hypertrophy and diastolic dysfunction: echocardiographic results of the HEBRO randomized
Doctor M. Kouremeti (Athens, GR)
Abstract
Presentation thumbnail
Sex specific associations between blood pressure in midlife and left ventricular hypertrophy in older women and men
Doctor E. Kringeland (Bergen, NO)
Abstract
Presentation thumbnail
Effects of colchicine on cardiac structure and function in patients with hypertension: a prespecified secondary analysis of the COlchicine HypERtENsion Trial (COHERENT)
Doctor A. Langhoff (Copenhagen, DK)
Abstract
Presentation thumbnail
Perception of self-efficacy improves adherence in hypertensive patients
Associate Professor A. Farcas (Cluj Napoca, RO)
Abstract
Presentation thumbnail
Gender, age and regional disparities in antihypertensive prescribing and medication adherence: evidence from linked survey and claims data
Professor S. Spethmann (Berlin, DE)
Abstract

Access the full session

Session thumbnail
Hypertension treatment (2)

The Event

Event poster

ESC Congress 2026

31 August 2026 09:15 CET
You may be interested in
thumbnail
Congress Presentation
Renal and cardiovascular benefits of treatment with angiotensin receptor blockers in patients with hypertension and chronic kidney disease: A systematic review and meta-analysis
1 September 2019
thumbnail
Congress Presentation
Successful perindopril/amlodipine+indapamide treatment as second line in uncontrolled hypertensive patients in line with european guidelines
7 April 2022
thumbnail
Congress Presentation
Acute changes in estimated glomerular filtration rate following initiation of dapagliflozin in patients with heart failure and reduced ejection fraction: insights from DAPA-HF
30 June 2021
thumbnail
Congress Presentation
Relationship of myocardial fibrosis markers with glomerular filtration rate in patients with arterial hypertension.
29 June 2021

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources